Quick Answer
Cue Biopharma, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
Cue Biopharma, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $4.20M | -47.7% |
| 2022 | $8.04M | — |
| 2021 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $1.33M | -74.3% | -41.9% |
| June 30, 2024 | $2.29M | -62.6% | -29.5% |
| March 31, 2024 | $3.24M | -54.2% | -22.8% |
| December 31, 2023 | $4.20M | -47.7% | -18.6% |
| September 30, 2023 | $5.16M | -42.6% | -15.7% |
| June 30, 2023 | $6.12M | -38.3% | -13.6% |
| March 31, 2023 | $7.08M | -28.2% | -11.9% |
| December 31, 2022 | $8.04M | — | -10.7% |
- Cue Biopharma, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: